C. Hermans

2.7k total citations · 1 hit paper
12 papers, 2.0k citations indexed

About

C. Hermans is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, C. Hermans has authored 12 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in C. Hermans's work include Sarcoma Diagnosis and Treatment (11 papers), Vascular Tumors and Angiosarcomas (10 papers) and Lymphoma Diagnosis and Treatment (3 papers). C. Hermans is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Vascular Tumors and Angiosarcomas (10 papers) and Lymphoma Diagnosis and Treatment (3 papers). C. Hermans collaborates with scholars based in Belgium, United Kingdom and Netherlands. C. Hermans's co-authors include Ian Judson, Jean‐Yves Blay, Jaap Verweij, Pancras C.W. Hogendoorn, M. van Glabbeke, Sandrine Marréaud, Jeremy Whelan, Jörg T. Hartmann, Patrick Schöffski and Cyril Fisher and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

C. Hermans

12 papers receiving 1.9k citations

Hit Papers

Doxorubicin alone versus intensified doxorubicin plus ifo... 2014 2026 2018 2022 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
    2014 814 citations Ian Judson, Jaap Verweij et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Hermans Belgium 10 1.4k 1.1k 508 277 208 12 2.0k
William Chu Canada 29 1.3k 0.9× 558 0.5× 48 0.1× 175 0.6× 479 2.3× 161 2.9k
James O. Cappellari United States 21 730 0.5× 501 0.4× 35 0.1× 180 0.6× 649 3.1× 43 1.7k
Sarah B. Fisher United States 26 624 0.4× 824 0.7× 64 0.1× 95 0.3× 704 3.4× 91 1.8k
Yasunori Nishida Japan 20 502 0.4× 246 0.2× 191 0.4× 37 0.1× 554 2.7× 96 1.8k
M. G. Pedersen Denmark 28 322 0.2× 449 0.4× 15 0.0× 462 1.7× 429 2.1× 54 2.3k
D S Schauwecker United States 23 208 0.1× 438 0.4× 77 0.2× 19 0.1× 751 3.6× 53 1.9k
Fumio Yamasaki Japan 21 282 0.2× 255 0.2× 42 0.1× 93 0.3× 181 0.9× 66 1.1k
M. Samson France 20 591 0.4× 101 0.1× 37 0.1× 151 0.5× 156 0.8× 81 1.6k
W. Paul Bowman United States 29 221 0.2× 773 0.7× 90 0.2× 479 1.7× 97 0.5× 83 4.4k
Stephen P. Creekmore United States 23 92 0.1× 901 0.8× 35 0.1× 196 0.7× 59 0.3× 45 2.0k

Countries citing papers authored by C. Hermans

Since Specialization
Citations

This map shows the geographic impact of C. Hermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Hermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Hermans more than expected).

Fields of papers citing papers by C. Hermans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Hermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Hermans. The network helps show where C. Hermans may publish in the future.

Co-authorship network of co-authors of C. Hermans

This figure shows the co-authorship network connecting the top 25 collaborators of C. Hermans. A scholar is included among the top collaborators of C. Hermans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Hermans. C. Hermans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Judson, Ian, Jaap Verweij, Hans Gelderblom, et al.. (2014). Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. The Lancet Oncology. 15(4). 415–423. 814 indexed citations breakdown →
2.
Richard, C., Iouli E. Gordon, Laurence S. Rothman, et al.. (2011). New section of the HITRAN database: Collision-induced absorption (CIA). Journal of Quantitative Spectroscopy and Radiative Transfer. 113(11). 1276–1285. 242 indexed citations
3.
4.
Blay, Jean‐Yves, Axel Le Cesne, Jeremy Whelan, et al.. (2006). Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. 24(18_suppl). 9517–9517. 7 indexed citations
5.
Pink, Daniel, Peter Reichardt, Ole S. Nielsen, et al.. (2005). Exatecan (DX-8951f), a new topoisomerase I - inhibitor, is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): A phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. 23(16_suppl). 9058–9058. 3 indexed citations
6.
Oosterom, A.T. van, H.T. Mouridsen, Ole S. Nielsen, et al.. (2002). Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. European Journal of Cancer. 38(18). 2397–2406. 130 indexed citations
7.
Švancárová, L, Jean‐Yves Blay, Ian Judson, et al.. (2002). Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer. 38(4). 556–559. 96 indexed citations
8.
Judson, Ian, John Radford, Martin Harris, et al.. (2001). Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. European Journal of Cancer. 37(7). 870–877. 296 indexed citations
9.
Nielsen, Ole S., Ian Judson, Q. van Hoesel, et al.. (2000). Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer. 36(1). 61–67. 108 indexed citations
10.
11.
Blay, Jean‐Yves, Ian Judson, Sjoerd Rodenhuis, et al.. (1999). Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti-Cancer Drugs. 10(10). 873–878. 13 indexed citations
12.
Woll, Penella J., Ian Judson, Siow Ming Lee, et al.. (1999). Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer. 35(3). 410–412. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Chu Breakdown of academic impact, for papers by James O. Cappellari Breakdown of academic impact, for papers by Sarah B. Fisher Breakdown of academic impact, for papers by Yasunori Nishida Breakdown of academic impact, for papers by M. G. Pedersen Breakdown of academic impact, for papers by D S Schauwecker Breakdown of academic impact, for papers by Fumio Yamasaki Breakdown of academic impact, for papers by M. Samson Breakdown of academic impact, for papers by W. Paul Bowman Breakdown of academic impact, for papers by Stephen P. Creekmore
Rankless by CCL
2026